The Global Health Body Issues Alert Over Acute Scarcity of Weight-Loss Jabs
Fewer than one in 10 people eligible to benefit from weight-loss injections including Wegovy are able to get them, states the WHO as it releases its initial recommendations on the medications.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for more widespread and fairer availability to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines acknowledges that obesity is a chronic disease that can be managed with comprehensive and ongoing support," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant hurdles to widespread availability to the injections that can assist patients in reducing significant weight, notes the agency.
GLP-1 Therapy Supply Crisis
Even in the present best projected outlook, the supply of GLP-1 therapies might only reach about 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The advice urges countries and companies to widen access, by approaches like licensing agreements.
Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is set to lapse in several nations in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs mimick a natural hormone to slow digestion, curb appetite and enhance feelings of fullness so people consume fewer calories.
Patients commonly see weight reduction after several weeks of commencing the once-weekly jabs.
Studies suggests patients may regain a significant portion after a year of halting the drug, when their usual food cravings resume.
Being carrying excess weight elevates your chance for developing health problems, like diabetes, heart disease, brain attack, and specific cancers.
Excess weight concerns people in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, per the health agency.
